US 12,220,400 B2
Amino acid compositions and methods for treating cystic fibrosis
Sadasivan Vidyasagar, Gainesville, FL (US); Astrid Grosche, Gainesville, FL (US); Xiaodong Xu, Gainesville, FL (US); Shanshan Lin, Gainesville, FL (US); and Sreekala Prabhakaran, Gainesville, FL (US)
Assigned to AmiLyfe, LLC, Norwood, MA (US); and University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Appl. No. 17/289,374
Filed by UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, Gainesville, FL (US)
PCT Filed Oct. 30, 2019, PCT No. PCT/US2019/058954
§ 371(c)(1), (2) Date Apr. 28, 2021,
PCT Pub. No. WO2020/092639, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/752,847, filed on Oct. 30, 2018.
Prior Publication US 2021/0393584 A1, Dec. 23, 2021
Int. Cl. A61K 31/401 (2006.01); A61K 31/198 (2006.01); A61K 31/47 (2006.01); A61K 45/06 (2006.01); A61P 11/00 (2006.01)
CPC A61K 31/401 (2013.01) [A61K 31/198 (2013.01); A61K 31/47 (2013.01); A61K 45/06 (2013.01); A61P 11/00 (2018.01)] 24 Claims
 
1. A pharmaceutical formulation comprising free amino acids:
the free amino acids consisting essentially of a therapeutically effective amount of each of cysteine and proline as free amino acids and
a therapeutically effective amount of at least one additional free amino consisting of free amino acids of glycine, tyrosine, valine, or lysine, or any combination thereof,
with the proviso that at least one of the free amino acids is an L-amino acid; and
optionally,
at least one pharmaceutically acceptable carrier, buffer, electrolyte, adjuvant, excipient, or water, or any combination thereof.